The news comes after CRISPR’s favorable data readouts in its sickle cell and beta thalassemia studies.
Cynata Therapeutics' Ross Macdonald, PhD, discusses the company's pipeline and clinical-phase trials.
Results of the phase 1 portion of ZUMA-4 support continued investigation into the efficacy of KTE-X19 in pediatric patients with B-cell acute lymphoblastic leukemia.
The director of the Mario Lemieux Center for Blood Cancers at UPMC Hillman Cancer Center discussed findings from the CARTITUDE studies.
Investigators find approach improved vision and visual fields in some patients.